ferritin heavy chain 1 pseudogene 13Genealiases: FTHL13 · FTHP3
Q-omics provides the consensus-scored FTH1P13 profile across patient tissues and cancer cell-line models. FTH1P13 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FTH1P13 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, FTH1P13 RNA expression shows 6,311 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, KIRC, and STAD as cancer lineages where FTH1P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTH1P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTH1P13 survival associations across molecular data types. FTH1P13 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTH1P13 RNA expression–survival associations across cancer types. High FTH1P13 expression shows unfavorable associations in UVM, STAD and UCEC, but favorable associations in THCA, LIHC and DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for FTH1P13 RNA expression.
This table summarizes FTH1P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FTH1P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTH1P13 shows lower tumor expression in PAAD and COAD and higher tumor expression in KIRC, THCA, KIRP and LIHC. The KIRC box plot shows higher FTH1P13 RNA expression in tumor versus normal tissue (log2 FC = +0.151, t-test p < 0.001).
This table shows molecular features associated with FTH1P13 in patient tissues and cancer cell lines. In patient samples, FTH1P13 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
